Blog

Can-Fite: Ophthalix Drug Effective for Eye Disease

April 27, 2012 | Comments are closed

OphthaliX (OTCBB: OPLI) has completed preclinical studies showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis. The pre-clinical study data demonstrated that CF101 is efficacious in preventing the clinical manifestations of Anterior Uveitis in a well-established animal model. The current study data together with the previous published...

Foamix Topical Foam Patented

April 26, 2012 | Comments are closed

Foamix has obtained a US Patent for its “Waterless Hydrophilic Foam” for Dermatological and Gynecological Drugs, such as Antibiotics, Antifungals, Corticosteroids, and Drugs for Psoriasis and Atopic Dermatitis. US Patent No. 8,114,385 , entitled “Oleaginous pharmaceutical and cosmetic foam ” covers a platform of versatile polyethylene glycol-based foam formulations, which...

BioPharma Equipment Pages Launched

April 16, 2012 | Comments are closed

GoIndustry DoveBid (LSE: GOI) has launched new industry-focused pages on its website, www.go-dove.com, in order to highlight its service offerings to a wide range of industries. The new pages can be accessed immediately at www.go-dove.com/industry and span the industries of BioPharma, Broadcast, Computing, Electronics, Food Services, Industrial, Transportation and more....

Canine VacciCheck Reaches U.S. Market

April 9, 2012 | Comments are closed

The Spectrum Group will market Biogal-Galed Labs’ VacciCheck™ product in the US pet market. The Canine VacciCheck™ kit is intended to be used as an in-house diagnostic tool to evaluate the amount of antibodies present for the core vaccines (Canine Infectious Hepatitis-Adenovirus Type 2, Canine Parvovirus, and Canine Distemper Virus)....

Redhill Trial for Migraine

March 16, 2012 | Comments are closed

RedHill Biopharma Ltd. (TASE: RDHL), has announced the commencement of a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of a leading triptan for the treatment of acute migraine. RedHill has completed screening and recruitment of all subjects for this clinical trial and announced subjects’ first dosing on...